【24h】

Pharmacokinetics of intravenous ibuprofen: Implications of time of infusion in the treatment of pain and fever

机译:静脉布洛芬的药代动力学:输注时间对疼痛和发烧的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Intravenous NSAIDs are playing an increasingly large role in analgesia, anti-inflammation and antipyresis in the hospitalized setting. For many years, ketorolac was the only intravenous NSAID available in the US, but in 2009 intravenous ibuprofen was approved by the US FDA for the treatment of pain and fever in adults. In developing intravenous ibuprofen, a range of times of infusion and dosing levels have been utilized and compared with the oral route of administration. The earliest studies utilized a 60-minute infusion, and later a 30-minute infusion was used for the pivotalregistration studies demonstrating efficacy and safety. Another recent trial in healthy volunteers demonstrated a safe and tolerable rapid infusion (57 minute) of intravenous ibuprofen. The pharmacokinetic data from all of the clinical trials on 400 and 800mg doses of intravenous ibuprofen were compiled, and pharmacokinetic modelling was utilized to simulate any data not acquired in the clinical studies. The pharmacokinetic profile of the following doses was modelled: 30-minute infusion of 800mg intravenous ibuprofen, 5- to 7-minute infusion of 400mg intravenous ibuprofen and 400mg ibuprofen oral tablet. These pharmacokinetic analyses revealed that, in general, maximum plasma concentration (Cmax) decreases considerably as the length of the infusion increases and that an oral dose is not able to achieve the Cmax level of any intravenous dose. For the rapid infusion, Cmax was twice that of the oral dose and, as expected, time to Cmax (tmax) was much more rapid than with the oral dose. However, the oral dose still maintained virtually 100 oral bioavailability. The efficacy of intravenous ibuprofen in terms of pain and fever has also been studied and this review found the drug to be efficacious for both indications. Future areas of study should include assessment of the analgesic and antipyretic efficacy of a rapid (5- to 10-minute) infusion and further assessment of pre-emptive administration of intravenous ibuprofen as part of a multimodal analgesic approach in the surgical setting.
机译:静脉内非甾体抗炎药在住院环境中的镇痛,抗炎和解热作用中起着越来越重要的作用。多年来,酮咯酸是美国唯一可用的静脉注射非甾体抗炎药,但2009年,静脉注射布洛芬获美国FDA批准用于治疗成人的疼痛和发烧。在开发静脉布洛芬时,已使用了一定范围的输注次数和剂量水平,并将其与口服给药途径进行了比较。最早的研究采用60分钟输注,后来30分钟的输注用于关键配准研究,证明了疗效和安全性。近期在健康志愿者中进行的另一项试验表明,静脉内布洛芬可以安全,可靠地快速输注(57分钟)。汇编了所有关于400和800毫克静脉注射布洛芬的临床试验的药代动力学数据,并利用药代动力学模型来模拟临床研究中未获得的任何数据。对以下剂量的药代动力学模型进行了建模:输注800mg静脉布洛芬30分钟,输注400mg静脉布洛芬和400mg布洛芬口服片剂5至7分钟。这些药代动力学分析表明,通常,最大血浆浓度(Cmax)随着输液时间的延长而显着降低,并且口服剂量无法达到任何静脉内剂量的Cmax水平。对于快速输注,Cmax是口服剂量的两倍,并且正如预期的那样,达到Cmax的时间(tmax)比口服剂量快得多。但是,口服剂量实际上仍保持100口服生物利用度。还已经研究了静脉注射布洛芬在疼痛和发烧方面的功效,该评价发现该药对两种适应症均有效。未来的研究领域应包括评估快速输注(5至10分钟)的止痛和解热效果,以及进一步评估在手术环境中作为多峰镇痛方法的一部分而先发制人的静脉注射布洛芬的镇痛效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号